Clinical Trial

JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL)

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated January 6, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of B-cell acute lymphoblastic leukemia (B-ALL)
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-07-18; most recent amendment 2025-12-31.
Trial Details
NCT Number NCT06514768
Lead Sponsor 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Conditions B-cell Acute Lymphoblastic Leukemia (B-ALL)
Enrollment 20 participants
Start Date 2024-06-20
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-06